Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Myocardial Perfusion Assessment With Multidetector Computed Tomography

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by Tennessee Heart and Vascular Institute, P.C..
Recruitment status was:  Active, not recruiting
General Electric
Information provided by:
Tennessee Heart and Vascular Institute, P.C. Identifier:
First received: February 17, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
Demonstrate the ability of muti-detector computed tomography to adequately perform stress testing will result in a veritable "one-stop shop" of non-invasive cardiac imaging that is, the ability to directly visualize heart arteries with high accuracy and to simultaniously determine the hemodynamic significance of any blockages visualized.

Condition Intervention Phase
Coronary Artery Disease
Device: Regadenoson (Lexiscan) [muti-detector computed tomography]
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Myocardial Perfusion Assessment With Multidetector Computed Tomography

Resource links provided by NLM:

Further study details as provided by Tennessee Heart and Vascular Institute, P.C.:

Primary Outcome Measures:
  • Diagnostic Accuracy (Sensitivity/Specificity/Positive Predictive Value/Negative Predictive Value) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Radiation dosimetry [ Time Frame: 6 months ]

Estimated Enrollment: 100
Study Start Date: February 2009
Estimated Study Completion Date: September 2009
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Regadenoson (Lexiscan) [muti-detector computed tomography]
    Regadenason, typical dosing
    Other Name: Lexiscan

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults >18 years of age
  • Adults undergoing myocardial perfusion SPECT imaging
  • Adults with suspected coronary artery disease

Exclusion Criteria:

  • Age <18
  • Known or suspected renal insufficiency (Creatinine <1.7 mg/dl)
  • Allergy to contrast
  • Inability or contraindication to lexiscan or beta blocker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00846079

United States, Tennessee
Tennessee Heart and Vascular Institute
Hendersonville, Tennessee, United States
Sponsors and Collaborators
Tennessee Heart and Vascular Institute, P.C.
General Electric
  More Information

Responsible Party: Tracy Callister,MD, Tennessee Heart and Vascular Institute, P.C. Identifier: NCT00846079     History of Changes
Other Study ID Numbers: THVI-101
Study First Received: February 17, 2009
Last Updated: February 17, 2009

Keywords provided by Tennessee Heart and Vascular Institute, P.C.:
coronary artery disease
stress testing

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Adenosine A2 Receptor Agonists
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 23, 2017